FDA releases a draft guidance outlining post-approval responsibilities facing manufacturers of generic drugs, highlighting requirements ranging from adverse event reporting and drug shortage notifications to labeling updates, promotional material submissions and compliance with Risk Evaluation and Mitigation Strategies.
Stakeholders at FDA's public hearing on the Commissioner’s National Priority Voucher program urge the agency to temporarily suspend the initiative and establish a more transparent framework governing its operation.
